Searched for
PDD HOLDINGS REVENUE ESTIMATES
Elon Musk's net worth crosses $980 billion as blockbuster SpaceX IPO price set at $135SpaceX's IPO has been priced at $135 per share, valuing the company at around $1.8 trillion and adding an estimated $188 billion to Elon Mu...- Revenue of auto ancillary firms grew at 11% CAGR during 2016-26: ReportAuto ancillary companies saw revenue grow at 11 percent annually from FY16 to FY26. Exports and increased vehicle content fueled this expan...
- Explained: Why Oracle shares crashed 10% in extended trading despite earnings beatOracle shares fell sharply in after-hours trading despite beating earnings estimates, as investors reacted to aggressive AI spending plans ...
- Honasa shares jump 6% on Rs 5,500 crore revenue target by FY31. What is Goldman Sachs saying?Honasa Consumer shares surged after the company outlined a revenue target of ₹5,500 crore by FY31. The guidance implies an annual growth ra...
- Oracle's AI spending blows past estimates, raising worries over growing debtOracle, which has major deals to build data centers for customers such as Meta Platforms and OpenAI, is working to position itself as a ma...
- Physicswallah is ‘class’ apart, says DAM Capital after initiating with Buy rating. 3 reasons whyDAM Capital has initiated coverage on PhysicsWallah with a Buy rating, calling the ed-tech firm ‘a class apart’ and highlighting strong gro...
- Suez Canal sees oil tanker surge amid Strait of Hormuz disruptionEgypt's Suez Canal saw a significant rise in oil tanker traffic and revenue in April. This surge is linked to the closure of the Strait of ...
- Meet Jayshree Ullal: Top-ranked Indian-origin woman on America’s richest self-made list with $6.8 billion net worthJayshree Ullal, ranked No. 7 on Forbes' America's Richest Self-Made Women list with a $6.8 billion net worth, has become a pivotal figure i...
- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- CMR Green Tech shares fall 8% after solid 43% stock market debut. Buy, sell or hold?CMR Green Technologies shares fell sharply from their post-listing highs after debuting at a 43% premium to the IPO price. While analysts r...
- Order book growth keeps Persistent Systems on trackPersistent Systems shares are rising, buoyed by optimism in the technology sector and advancements in artificial intelligence. The company ...
- Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...
- GDP growth momentum intact, no need for additional borrowing so far: Govt sourcesIndia's economy is navigating external challenges like rising import costs. However, domestic consumption remains strong, ensuring growth m...
- SpaceX IPO: Great business, wrong price? Why Aswath Damodaran is skipping Musk’s mega offeringDespite the excitement surrounding SpaceX’s highly anticipated IPO, valuation expert and NYU professor Aswath Damodaran plans to stay away ...
- Zepto IPO: Aadit Palicha, Kaivalya Vohra to hold stake; Nexus Ventures biggest seller in OFSQuick commerce firm Zepto's promoters will not dilute equity in its upcoming IPO, which aims to raise Rs 8,010 crore via fresh issue and an...
- FIFA 2026: Brokerages bet on sector winners as soccer World Cup set to kick offThe 2026 FIFA World Cup will bring billions to host nations. Analysts expect a surge in spending on hotels, airlines, and retail. Beer sale...
- Asia tech selloff is a buying opportunity, says Manishi Raychaudhuri; but India has a problem to fix firstAsian markets saw a sharp sell-off in tech stocks this week. Investor Manishi Raychaudhuri views this as a buying chance. India's market fa...
- Telecom revenue growth may slip to single digits without tariff hikeTelecom revenue growth may slow to single digits this year without tariff increases. Operators are delaying hikes due to inflation. A poten...
- UBS downgrades BHEL shares to Neutral from Buy. Check target, key reasonsUBS has downgraded BHEL to "Neutral" from "Buy", citing a more balanced risk-reward outlook after the stock's strong run, though it raised ...
- Broadcom's second-quarter revenue misses estimates as competition bitesSecond-quarter revenue came in at $22.19 billion, missing estimates of $22.27 billion, as Broadcom races with Nvidia whose dominant graphic...
Load More
